$1,318.00
This Market Spotlight report covers the Huntington’s Disease market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, recent events and analyst opinion, probability of success, licensing and asset acquisition deals, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Huntington’s Disease market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, recent events and analyst opinion, probability of success, licensing and asset acquisition deals, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
9 TREATMENT
9 Treatment of chorea
9 Treatment of parkinsonism
9 Treatment of behavioral and psychiatric dysfunction
10 EPIDEMIOLOGY
14 MARKETED DRUGS
16 PIPELINE DRUGS
21 RECENT EVENTS AND ANALYST OPINION
21 ANX-005 for HD (January 4, 2022)
22 Ingrezza for HD (December 7, 2021)
24 Multiple Drugs for HD (March 29, 2021)
25 Tominersen for HD (March 22, 2021)
26 TV-7820 for HD (December 8, 2020)
29 KEY UPCOMING EVENTS
30 PROBABILITY OF SUCCESS
31 LICENSING AND ASSET ACQUISITION DEALS
31 Deal Watch: MegaPharm Signs Agreement For SOM Biotech’s SOM3355
31 Roche Jumps Back Into Huntington’s With Spark/NeuExcell Partnership
31 Ipsen Targets External Innovation With Exicure Option In Rare Neurodegenerative Disorders
32 REVENUE OPPORTUNITY
33 CLINICAL TRIAL LANDSCAPE
34 Sponsors by status
35 Sponsors by phase
36 Recent events
38 BIBLIOGRAPHY
39 APPENDIX
LIST OF FIGURES
12 Figure 1: Trends in prevalent cases of HD, 2019–28
16 Figure 2: Overview of pipeline drugs for HD in the US
16 Figure 3: Pipeline drugs for HD, by company
17 Figure 4: Pipeline drugs for HD, by drug type
17 Figure 5: Pipeline drugs for HD, by classification
28 Figure 6: TV-7820 for HD (December 8, 2020): Phase II – PRIDE-HD
29 Figure 7: Key upcoming events in HD
30 Figure 8: Probability of success in the neurodegenerative pipeline
33 Figure 9: Clinical trials in HD
33 Figure 10: Top 10 drugs for clinical trials in HD
34 Figure 11: Top 10 companies for clinical trials in HD
34 Figure 12: Trial locations in HD
35 Figure 13: HD trials status
36 Figure 14: HD trials sponsors, by phase
LIST OF TABLES
11 Table 1: Prevalent cases of HD, 2019–28
13 Table 2: Prevalence proportions of HD, 2019–28
15 Table 3: Marketed drugs for HD
18 Table 4: Pipeline drugs for HD in the US
21 Table 5: ANX-005 for HD (January 4, 2022)
23 Table 6: Ingrezza for HD (December 7, 2021)
25 Table 7: Multiple Drugs for HD (March 29, 2021)
26 Table 8: Tominersen for HD (March 22, 2021)
27 Table 9: TV-7820 for HD (December 8, 2020)
32 Table 10: Historical global sales, by drug ($m), 2017–21
32 Table 11: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!